1,209 reports of this reaction
8.1% of all LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN reports
#3 most reported adverse reaction
DEATH is the #3 most commonly reported adverse reaction for LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, manufactured by Novartis Pharmaceuticals Corporation. There are 1,209 FDA adverse event reports linking LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN to DEATH. This represents approximately 8.1% of all 14,999 adverse event reports for this drug.
Patients taking LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN who experience death should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DEATH is moderately reported among LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN users, representing a notable but not dominant share of adverse events.
In addition to death, the following adverse reactions have been reported for LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN:
The following drugs have also been linked to death in FDA adverse event reports:
DEATH has been reported as an adverse event in 1,209 FDA reports for LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN. This does not prove causation, but indicates an association observed in post-market surveillance data.
DEATH accounts for approximately 8.1% of all adverse event reports for LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, making it one of the most commonly reported side effect.
If you experience death while taking LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.